Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Prior treatment

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Treatment with any investigational drug within 30 days prior to initiation of Saxenda® treatment.

Other illness

• Known or suspected hypersensitivity to Saxenda® , the active substance or any of the excipients
• Patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other

• Female patient who is pregnant, breast-feeding, or intends to become pregnant.
• Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation

• Male or Female of Taiwanese patients, age above or equal to 12 years who are under Saxenda® treatment or are scheduled to treat with Saxenda® according to approved label in Taiwan based on the clinical judgment of their treating physician.
• Patients should have baseline (pre-dosing) values, including body height, weight and initial dosage of Saxenda® .
• The decision to initiate treatment or to have started with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the physician independently from the decision to join this study.
• Informed consent obtained before collection of clinical data for this study. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.